| Literature DB >> 31947834 |
Anna Graczyk1, Roza Pawlowska1, Dominika Jedrzejczyk1, Arkadiusz Chworos1.
Abstract
Development of nanotechnology has become prominent in many fields, such as medicine, electronics, production of materials, and modern drugs. Nanomaterials and nanoparticles have gained recognition owing to the unique biochemical and physical properties. Considering cellular application, it is speculated that nanoparticles can transfer through cell membranes following different routes exclusively owing to their size (up to 100 nm) and surface functionalities. Nanoparticles have capacity to enter cells by themselves but also to carry other molecules through the lipid bilayer. This quality has been utilized in cellular delivery of substances like small chemical drugs or nucleic acids. Different nanoparticles including lipids, silica, and metal nanoparticles have been exploited in conjugation with nucleic acids. However, the noble metal nanoparticles create an alternative, out of which gold nanoparticles (AuNP) are the most common. The hybrids of DNA or RNA and metal nanoparticles can be employed for functional assemblies for variety of applications in medicine, diagnostics or nano-electronics by means of biomarkers, specific imaging probes, or gene expression regulatory function. In this review, we focus on the conjugates of gold nanoparticles and nucleic acids in the view of their potential application for cellular delivery and biomedicine. This review covers the current advances in the nanotechnology of DNA and RNA-AuNP conjugates and their potential applications. We emphasize the crucial role of metal nanoparticles in the nanotechnology of nucleic acids and explore the role of such conjugates in the biological systems. Finally, mechanisms guiding the process of cellular intake, essential for delivery of modern therapeutics, will be discussed.Entities:
Keywords: AuNP; RNAi; cellular uptake; gene expression regulation; structural RNA
Year: 2020 PMID: 31947834 PMCID: PMC6982881 DOI: 10.3390/molecules25010204
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Different forms of nucleic acids. (A) Structural forms of nucleic acids: linear or circular duplexes, spherical nucleic acids; (B) modes of assembly: native RNA structures, natural scaffolds, synthetically programmed, synthetic scaffolds. Adapted with modification [14].
Figure 2Biomedical applications of nanoparticles through conjugation with various active moieties including nucleic acids, peptides, receptors, antibodies, and small molecules. Taken with permission from [9].
Figure 3Assembly of two-dimensional (2D) arrays. Taken with permission from [110]. (1) (a) Where two domains (cyan bonding to magenta and brown bonding to red) are involved in array formation, while the end of the third domain (blue or green) is free to be involved in scaffolding operations; (b) nanoparticle attachment (5 nm particles attached to only one of the two triangular tiles, 5 nm particles attached to both of the tiles, and 5 nm particles attached to one of the tiles and 10 nm particles attached to the other tile); (c) tapping-mode atomic force micrograph of an underivatized array. (2) Schematic formation of 2D DNA-AuNP arrays. (3) Transmission electron micrographs of 2D arrays of organized gold nanoparticles. (a) An array where one tile contains 5 nm particles. (b) An array where both tiles contain 5 nm particles. (c) An array where one tile contains a 5 nm particle and the other tile contains a 10 nm particle.
Figure 4Casting metal nanoparticles (NPs) with prescribed shapes using DNA nanostructure molds. (a) Scheme of the nanostructure synthesis. Molds with an inner cavity are fabricated using the DNA origami method. Capture DNA strands in the center of the cavity allow the site-specific introduction of single gold nanoparticle (AuNP) seeds carrying DNA strands with the complementary sequence. In the presence of a gold precursor and a reducing agent, the growth of the nanoparticle is initiated. Further gold deposition is blocked by the mold walls, such that the particle adopts the shape that is dictated by the mold; (b) Cartoon of the DNA mold with DNA double-helices depicted as gray cylinders and capture strands as orange spirals; (c) TEM images of the mold; (d) TEM images of the mold with bound gold nanoparticle seed. In panels c and d, the top and bottom rows show, respectively, views onto a mold side wall and along the cavity axis. All TEM images are shown at equal magnification with the scale bar corresponding to 40 nm. Taken with permission from [119].
Figure 5Schematic synthesis of thiol-linked spherical nucleic acids. Gold nanoparticles are synthesized from chloroauric acid in the presence of citrate; obtained AuNPs are treated with bis-(p-sulfonatophenyl)phenylphosphine (BSPP) to replace citrate ions prior to attachment of tiolated nucleic acids.
Figure 6Examples of electrostatic RNA-gold nanoparticle interactions. (A) RNA entrapped within the dendronized polymer layer [152]. (B) Hierarchical supramolecular assembly of TS ladder decorated with cationic AuNPs [150]. (C) Layer by layer deposition of siRNA and poly(ethylene imine) (PEI) on the surface of AuNPs [151] (blue represents PEI, green represents siRNA). Taken with permission from: A [152], B [150], C [151].
Figure 7Schematic summary of the endocytosis mechanisms involved in the cellular uptake of spherical nucleic acids (SNAs). SR denotes the scavenger receptor. Taken with permission from [199].
Comparison of gold nanoparticles toxicity and subcellular localization [202].
| AuNP Size (nm) | Surface Group | Cell Line | Toxicity | Subcellular Localization | Reference |
|---|---|---|---|---|---|
| 1, 4 | Phospholipid | HeLa | Not reported | Lysosomal, perinuclear/nuclear | [ |
| 2, 8 | Tat peptide | HTERT-BJ1 | Low cytotoxicity below 10 µM | Cytoplasmic around the mitochondria and nuclear | [ |
| 3, 7 | PEG | HeLa | Non toxic | Nuclear | [ |
| 5, 10, 15 | CALNN, TAT and/or HA2 viral peptides | HeLa | Not reported | Cytoplasmic vesicles, lysosomal, endosomal, membranes | [ |
| 10 | Oligonucleotides | HaCaT, A549, BALB/c 3T3, C166 | Not reported | Cytoplasmic, endosomal | [ |
| 11–32 | Nucleoplasmin | BALB/c 3T3 A31, MOP-8, SV-T2 | Not reported | Nuclear and cytoplasmic | [ |
| 12 | Sweet arrow peptide (SAP) | HeLa | Not reported | Endosomal | [ |
| 13 | PEG | In vivo studies | Induction of acute inflammation and apoptosis | Cytoplasmic vesicles and lysosomal | [ |
| 16 | PEG, CALNN, NLS, CPPs | HeLa | Not reported | Cytoplasmic, nuclear, lysosomal | [ |
| 20 | citrate (Cit) compared with 11-mercaptoundecanoic acid (11-MUA) | HepG2 | Non-toxic, DNA damage in Cit-AuNPS | Cytoplasmic, endosomal | [ |
| 20 | BSA with NLS, receptor-mediated endocytosis peptides (RME) | HepG2 | 5% death | Nuclear | [ |
| 20 | Biotinylated Tat-HA2, PEG-SH, anti-actin antibodies | BALB/c 3T3 | Not reported | Cytoskeleton (cytoplasmic) | [ |
| 20–50 | Citrate, PEG, CPP, Trastuzumab | DLD-1, SKOV-3, MDA-MB-231, SKBR-3, MCF-7 | Cytotoxicity dependent on the surface group. | Intracellular | [ |
| 30–90 | PEG | PC-3 | Non toxic | Cytoplasmic and nuclear | [ |
| 14–100 | Transferrin | STO, HeLa, SNB19, NPC | Non toxic | Endosomal | [ |
| 100 | DPPE | C-32 | Non toxic | Endosomal | [ |